Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
2009 · Molecular Cancer · 175 citations
https://doi.org/10.1186/1476-4598-8-118